Pfizer’s second quarter results reflected stability in its core business despite ongoing challenges in COVID-related product demand. The company’s performance was shaped by strong execution in its non-COVID portfolio, with management highlighting robust revenue contributions from acquired brands and recent launches. CEO Albert Bourla attributed operational progress to “continued strategic progress” and emphasized the value generated by recent acquisitions such as Seagen and Biohaven. Management also pointed to the success of brands like Eliquis and Padcev, noting that commercial teams “performed with excellence and precision” across major therapeutic areas.
Is now the time to buy PFE? Find out in our full research report (it’s free for active Edge members).
Pfizer (PFE) Q2 CY2026 Highlights:
- Revenue: $15.03 billion vs analyst estimates of $14.4 billion (2.6% year-on-year growth, 4.4% beat)
- Adjusted EPS: $0.77 vs analyst estimates of $0.68 (12.9% beat)
- The company slightly lifted its revenue guidance for the full year to $61.5 billion at the midpoint from $61 billion
- Management reiterated its full-year Adjusted EPS guidance of $2.90 at the midpoint
- Operating Margin: 27.9%, in line with the same quarter last year
- Organic Revenue rose 1% year on year
- Market Capitalization: $154.2 billion
While we enjoy listening to the management’s commentary, our favorite part of earnings calls is the analyst questions. Those are unscripted and can often highlight topics that management teams would rather avoid or topics where the answer is complicated. Here is what has caught our attention.
Our Top 5 Analyst Questions From Pfizer’s Q2 Earnings Call
- Evan Seigerman (BMO Capital Markets) asked about the benchmarks for success in the upcoming MEVPRO-1 prostate cancer trial; Chief Scientific Officer Chris Boshoff clarified that a clinically meaningful benefit of 30% over standard care would validate the mechanism.
- Christopher Schott (JPMorgan) questioned the drivers behind the non-COVID revenue guidance increase and Padcev’s growth outlook; Interim CFO Cecile Guegan pointed to broad strength across key brands, with Padcev expected to moderate but remain a major growth engine.
- Umer Raffat (Evercore ISI) inquired about the commercial potential of mevrometostat; Commercial Chief Aamir Malik emphasized its global opportunity and scale across the disease continuum if approved.
- Akash Tewari (Jefferies) probed efficacy and future plans for atirmociclib and the impact of proposed changes to 340B hospital payments; Boshoff highlighted atirmociclib’s tolerability and planned adjuvant trials, while CEO Bourla noted regulatory uncertainty on reimbursement changes.
- Terence Flynn (Morgan Stanley) pressed on the sustainability of the dividend amid business development constraints; CEO Bourla asserted that even under stressed scenarios, the dividend would be maintained and could eventually grow post patent expirations.
Catalysts in Upcoming Quarters
In the next several quarters, the StockStory team will be watching (1) clinical readouts for late-stage oncology and obesity programs, (2) the pace of cost savings realization and manufacturing optimization, and (3) the expansion of commercial uptake for recently acquired brands and new product launches. Progress on artificial intelligence integration and further regulatory milestones will also be important indicators of execution.
Pfizer currently trades at $26.97, up from $25.03 just before the earnings. At this price, is it a buy or sell? See for yourself in our full research report (it’s free).
High-Quality Stocks for All Market Conditions
ALSO WORTH WATCHING: Top 5 Momentum Stocks. The best time to own a great stock is when the market is finally noticing it. These aren’t just high-quality businesses. Something is happening with them right now. Elite fundamentals meet near-term momentum — both boxes checked at the same time.
Find out which stocks our AI platform is flagging this week. See this week’s Strong Momentum stocks — FREE. Get Our Strong Momentum Stocks for Free HERE.
Stocks that have made our list include now familiar names such as Nvidia (+1,460% between June 2020 and June 2025) as well as under-the-radar businesses like the once-micro-cap company Tecnoglass (+1,552% between June 2020 and June 2025). Find your next big winner with StockStory today.
